Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation, a leading research and advocacy organization, to find and more widely treat undiagnosed patients living with a common genetic condition that causes very high levels of unhealthy cholesterol, heightening the risk for heart attacks and strokes even at a young age.
News | STEMI
Emory Doctors and Family Heart Foundation Team Up to Help Patients with Dangerously High Cholesterol Caused by Genetic Condition

December 15, 2022 —  Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation ...

Home December 15, 2022
Home
Corindus, A Siemens Healthineers Company, has officially rebranded as Siemens Healthineers
News | Cardiovascular Business
Corindus, A Siemens Healthineers Company, Is Now Siemens Healthineers Endovascular Robotics

December 14, 2022 — Corindus, A Siemens Healthineers Company, has been rebranded to Siemens Healthineers Endovascular ...

Home December 14, 2022
Home
Series to feature leading experts discussing the current and future trends in the carotid treatment market
News | Stents Carotid
InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home December 13, 2022
Home
Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.
News | Structural Heart
Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single ...

Home December 13, 2022
Home
The U.S. Food and Drug Administration (FDA) is alerting health care facilities and providers of a shortage of Getinge Maquet/Datascope Intra-Aortic Balloon Pump (IABP) devices,
News | Catheters
Getinge Maquet/Datascope Intra-Aortic Balloon Pump (IABP) Shortage - Letter to Health Care Providers

December 5, 2022 —  The U.S. Food and Drug Administration (FDA) is alerting health care facilities and providers of a ...

Home December 05, 2022
Home
Ms. Nieves, donor family, and doctors. Photo courtesy of Montefiore Health System.
News | Heart Failure
World's First HIV-Positive to HIV-Positive Heart Transplant Recipient Meets Donor Family, Shares Gratitude for Life & Advocates for Organ Donation

December 2, 2022 —  Westchester resident, 62-year-old Miriam Nieves, is especially grateful this Thanksgiving season ...

Home December 02, 2022
Home
Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic Valve System.
News | Structural Heart
Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2 Aortic Valve System

December 2, 2022 —  Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

Home December 02, 2022
Home
A team led by UTHealth Houston's K. Lance Gould, MD, (center) used PET imaging technology (shown above) to map coronary blood flow and its outcomes among heart disease patients. (Photo by UTHealth Houston)
News | PET Imaging
PET Technology More Effective Than Angiogram at Determining Need for Coronary Stents, Bypass Surgery

December 1, 2022 —  A new method for determining whether patients with heart disease need coronary stents or bypass ...

Home December 01, 2022
Home
Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic Valve System.
News | Structural Heart
Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2 Aortic Valve System

November 30, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

Home November 30, 2022
Home
BIOTRONIK announced their presentation of the one-year results from the investigator-initiated BIOPACT RCT this week
News | Drug-Eluting Balloons
One-Year BIOPACT Randomized Controlled Trial (RCT) Results Demonstrate Excellent Results for Low-Profile Passeo-18 Lux DCB

November 28, 2022 – BIOTRONIK announced the presentation of one-year results from the investigator ...
Home November 28, 2022
Home
CroĂ­Valve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve technology for the treatment of Tricuspid Regurgitation as part of its TANDEM I study in Poland.
News | Heart Valve Technology
CroĂ­Valve Reports Successful First in Human Implants of its DUO Tricuspid Coaptation Valve System

November 22, 2022 — CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve ...

Home November 22, 2022
Home
UH Cleveland Medical Center. Image courtesy of University Hospitals
News | Deep Vein Thrombosis (DVT)
Four Prospective, Multicenter Studies Support Use of Drug-Coated Balloons Over Bare Metal Stents in Treating Femoropopliteal Lesions

November 21, 2022 —  New research published in the Journal of the American College of Cardiology shows the use of drug ...

Home November 21, 2022
Home
Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System
News | Antiplatelet and Anticoagulation Therapies
Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

Home November 14, 2022
Home
Cryoablation involves guiding a small tube into the heart and inflating a small balloon to kill problematic tissue with cold temperatures. Image courtesy of Medtronic
News | Atrial Fibrillation
National Study Suggests It's Time to Rethink How We Treat Atrial Fibrillation

November 10, 2022 —  A national study led by UBC researchers at the Centre for Cardiovascular Innovation is shedding ...

Home November 10, 2022
Home
Feature | Angiography | By Bhvita Jani
Interventional X-ray and Mobile C-arm Equipment Markets Had a Double-digit Recovery in 2021

The world market for interventional X-ray and mobile C-arm equipment is forecast to reach over $4.9 billion by 2026 ...

Home November 09, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now